Skip to content

Public FDA record

Z-1263-2020: i-STAT CG4+ cartridge (blue), List No. 03P85-50. UDI (01) 00054749002269 - Product Usage: The i-STAT CG4+

Recall record Z-1263-2020 for Abbott Point Of Care Inc.. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-1263-2020
Company in FDA record
Abbott Point Of Care Inc.
FDA classification date
Feb 18, 2020
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 16, 2026
Recall classification
Class II

Reason stated in the source

The I-STAT BLUE CHEM8+ and CG4+ cartridges are not FDA cleared and do not have CLIA waived status. CLIA recognizes two types of laboratory tests: waived and non-waived. Different CLIA standards apply to waived and non-waived tests as well as the facilities that perform these types of tests. The i-STAT CHEM8+ cartridge contains nine measured assays (sodium, potassium, chloride, blood urea nitrogen (BUN), ionized calcium, TCO2, glucose, creatinine and hematocrit) and is categorized as a CLIA waived test for venous whole blood samples, meaning this cartridge could be used in a facility with a CLIA Certificate of Waiver as a waived test.

Source facts

Action
On 1/15/2020, the firm notified customers of the product recall via letters, customer emails, follow-up phone calls/visits by sales representatives, and a website posting at www.pointofcare.abbott. Customers were instructed to do the following: Facilities using the i-STAT BLUE CHEM8+ cartridges in CLIA waived settings should transition to alternate CLIA waived testing methods or engage a reference laboratory for the tests your facility requires. Facilities should discontinue use of the i-STAT BLUE CHEM8+ and CG4+ cartridges with capillary samples. Facilities should use an alternate method, if available, for the tests included in the i-STAT BLUE CHEM8+ and CG4+ cartridges for arterial and venous specimens. If an alternate method is not available, the BLUE CHEM8+ and CG4+ cartridges will still be available while Abbott is working toward FDA clearance for facilities in non-waived settings (i.e., facilities that hold a Certificate of Compliance or Accreditation). Abbott will notify customers if/when the products receive FDA clearance for use with arterial and venous whole blood samples in non-waived settings. However: " Facilities that continue to use the BLUE CHEM8+ and CG4+ cartridges for arterial and venous specimens should inform clinicians and laboratory staff that the performance of these cartridges has not yet been fully characterized. " Clinicians should be advised to consider a patients signs, symptoms, history, and results of other diagnostic tests when interpreting results from these cartridges. If the results do not match the patients clinical presentation, the patient sample should be retested using an alternate test method or a reference laboratory. In order to mitigate risk associated with the performance of these products not yet being fully characterized, Abbott will be actively monitoring the performance of these cartridges. Please report any questions or concerns you have about their performance to Abbott Point of Care Technical Support
Initiated
2020-01-15
Root cause
No Marketing Application
Terminated
2021-03-02
Distribution
US Nationwide distribution.
Recall number
Z-1263-2020
Recall status
Terminated
CDRH record ID
179123
FDA classified
2020-02-18
Recall event number
84728

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗